ScienceDaily (Nov. 10, 2008) — Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory.

Treatment of Ewing sarcoma that relapses is difficult. A new study published in Pediatric Blood & Cancer evaluated a phase II clinical trial of a potential new treatment approach for relapsed Ewing sarcoma using cytarabine.

Ten patients were treated. While one patient's tumor stayed stable in size for approximately 4 months while receiving the drug, none of the ten patients had smaller tumors after treatment with cytarabine. This result is disappointing since laboratory studies indicated that cytarabine might be an effective drug for these patients. In addition, these patients with Ewing sarcoma developed lower blood counts than expected from these doses of cytarabine. The fact that the drug was not found to be effective is yet another example in which laboratory data do not always translate into success in treating patients.

"Cytarabine is not an effective agent for patients with Ewing sarcoma and this drug should be used with caution in heavily pretreated patients with solid tumors due to the significant impact of the drug on blood counts," says Steven DuBois, co-author of the study. This study demonstrates the difficulties of extending promising therapeutic targets observed in the laboratory to effective treatments in patients. It also emphasizes the need for more predictive preclinical models.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Wiley-Blackwell, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Related Stories

Discovery Of The Cellular Origin Of Ewing's Sarcoma (May 21, 2007) — Scientists have identified the cells that cause Ewing's sarcoma. They are cells of the mesenchyme, the connective tissue that supports other tissues. The researchers have also succeeded in ...  > read more

New Hope For Deadly Childhood Bone Cancer: Surprising Discovery Made By Studying 'Junk DNA' (Sep. 1, 2009) — Researchers have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors ...  > read more

Caucasians Are At Higher Risk Of Developing Ewing's Sarcoma Than Other Races (June 23, 2009) — The largest analysis of its kind has found that Caucasians are much more likely that people in other racial/ethnic groups to develop a rare bone and soft tissue cancer called Ewing's sarcoma. In ...  > read more

Therapeutic Targets Found for Rare Cancer in Children (Sep. 13, 2010) — The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific ...  > read more

Search ScienceDaily